Model predicted clinical outcomes over lifetime unless otherwise stated
| Component | ACEI | Sacubitril/valsartan | Incremental | ||||||
| UK | Denmark | Colombia | UK | Denmark | Colombia | UK | Denmark | Colombia | |
| Life expectancy, years | 8.36 | 7.34 | 7.95 | 9.27 | 8.07 | 8.78 | 0.91 | 0.73 | 0.83 |
| Number of HF hospitalisations per patient | 0.89 | 0.82 | 0.85 | 0.84 | 0.76 | 0.79 | −0.05 | −0.05 | −0.05 |
| Number of CV hospitalisations per patient | 2.18 | 2.01 | 2.08 | 2.06 | 1.88 | 1.95 | −0.13 | −0.13 | −0.13 |
| All-cause hospitalisations | 3.50 | 3.22 | 3.34 | 3.30 | 3.01 | 3.13 | −0.20 | −0.21 | −0.21 |
| All-cause mortality (%) at year 2 | 16% | 20% | 17% | 14% | 17% | 15% | −0.02 | −0.02 | −0.02 |
| All-cause mortality (%) at year 5 | 38% | 44% | 40% | 33% | 40% | 36% | −0.05 | −0.04 | −0.04 |
| All-cause mortality (%) at year 10 | 66% | 72% | 68% | 60% | 67% | 63% | −0.05 | −0.04 | −0.05 |
ACEI, angiotensin-converting-enzyme inhibitor; CV, cardiovascular; HF, heart failure.